Adams Respiratory Therapeutics Inc

Adams Respiratory Therapeutics — Q4 FY2006 Earnings Presentation

22 slides from Adams Respiratory Therapeutics's earnings presentation, Aug 24, 2006

  1. Slide 1: Fiscal 2006 and Fiscal Fourth Quarter Earnings Conference Call

    Slide 1: Fiscal 2006 and Fiscal Fourth Quarter Earnings Conference Call

    Adams Respiratory Therapeutics Fiscal 2006 and Fiscal Fourth Quarter Earnings Conference Call - August 24, 2006 Early 2006 Ending 2006

  2. Slide 2: Safe Harbor

    Slide 2: Safe Harbor

    Safe Harbor This presentation contains certain "forward-looking" statements. These statements are based on the current estimates and assumptions of the management of Adams Respiratory Therapeutics, Inc. (or "Adams") as of the date of this presentation and are naturally subject to uncertainty and cha

  3. Slide 3: Fourth Quarter Financial Highlights

    Slide 3: Fourth Quarter Financial Highlights

    Fourth Quarter Financial Highlights Net sales increased 35% to $52.8 million Doubled pretax income to $11.0 million Income per diluted share increased to $0.17

  4. Slide 4: Delsym Acquisition

    Slide 4: Delsym Acquisition

    Delsym(r) Acquisition Only 12-hour OTC cough liquid U.S. launch: December 1982 Unique Pennkinetic(r) technology 12-hour duration of action Superior taste masking Alcohol free Formulation patent (2017) Listed in FDA Orange Book 4 SKU's: 2 Adult/2 Children

  5. Slide 5: Mucinex for Children

    Slide 5: Mucinex for Children

    Mucinex(r) for Children Great-tasting* Precise dosing Offers base-brand end benefit: "Mucinex in...Mucus Out!"(tm) Source: Company sponsored research.

  6. Slide 6: Production Capacity Improving

    Slide 6: Production Capacity Improving

    Production Capacity Improving Jan. 2006 Run Rate Q3 FY 06 Run Rate Current Run Rate Early CY 07 Run Rate $250 MM $400 MM $340 - $350 MM Includes existing facilities & equipment $100 MM $200 MM $300 MM $400 MM $500 MM $450+ MM Upon completion of several capital projects underway at Ft. Worth facility

  7. Slide 7: FY 2006 Operating Highlights

    Slide 7: FY 2006 Operating Highlights

    FY 2006 Operating Highlights Secured guaifenesin supply, more than doubled manufacturing capacity Tripled our product portfolio from 2 to 6 items Nearly doubled Mucinex(r) brand awareness and market share in the cough/cold/allergy sinus category(1) Consumption up 50%(2) (1) Internal research (2) Acc

  8. Slide 8: FY 2006 Operating Highlights

    Slide 8: FY 2006 Operating Highlights

    FY 2006 Operating Highlights Launched second season of award- winning Mucinex(r) advertising Granted 2nd patent from the U.S. PTO Ended fiscal year 2006 with about 220 Adams' employees* Improved our financial position *Excludes the approximately 300 employees added as of Aug. 1 with the repurchase o

  9. Slide 9: Fiscal 2006 Financial Highlights

    Slide 9: Fiscal 2006 Financial Highlights

    Fiscal 2006 Financial Highlights Net sales increased 49% to $239.1 million Pretax income increased 71% to $76.2 million SG&A expenses increased 27% to $99.0 million; conducted a $35 million consumer advertising campaign Development expenses increased 156% to $18.9 million(1) Income per diluted share

  10. Slide 10: Fiscal 2006 Product Portfolio

    Slide 10: Fiscal 2006 Product Portfolio

    $158.6 MM $59.2 MM $19.3 MM Launched 10/05 $1.3 MM Launched 3/06 Fiscal 2006 Product Portfolio Fiscal 2006 Net Sales increased 49% to $239.1 MM Platform technologies: Mucinex(r) and Humbid(r) franchises: extended release guaifenesin Delsym(r): Unique Pennkinetic(r) system with 12 hour duration of ac

  11. Slide 11: Mucinex: Market Share Gains

    Slide 11: Mucinex: Market Share Gains

    Mucinex(r): Market Share Gains Source: Information Resources, Inc. (IRI)4, 12, and 52-week periods c/c/a/s category. $ Share

  12. Slide 12: Fiscal 2006 Product Portfolio

    Slide 12: Fiscal 2006 Product Portfolio

    $158.6 MM $59.2 MM $19.3 MM Launched 10/05 $1.3 MM Launched 3/06 Fiscal 2006 Product Portfolio Fiscal 2006 Net Sales increased 49% to $239.1 MM Platform technologies: Mucinex(r) and Humbid(r) franchises: extended release guaifenesin Delsym(r): Unique Pennkinetic(r) with 12 hour duration of action $0

  13. Slide 13: Consumer Advertising and Line Extensions

    Slide 13: Consumer Advertising and Line Extensions

    Consumer Advertising February 2006 Competing Product Removal? Competing Product Removal? Repeat Success with Mucinex(r) Line Extensions Consumer Advertising November 2004 Competing Products Removed December 2003 Launched July 2002 Approved July 2002 $125 MM Rx market $27 MM Rx market Consumer Advert

  14. Slide 14: U.S. Development of Erdosteine

    Slide 14: U.S. Development of Erdosteine

    U.S. Development of Erdosteine 2005: In-licensed mucoregulator compound with a unique activity profile Full blown development project; investment of $50 - $60 million if ultimately successful Approved in > 30 foreign markets; ~24 million patient exposures Phase IIb clinical program underway (March 2

  15. Slide 15: Adams' Strategy

    Slide 15: Adams' Strategy

    Adams' Strategy Build internal pipeline by extending guaifenesin platform to other OTC & Rx respiratory segments Aggressively in-license/acquire new respiratory products Three - pronged strategy Drive Mucinex(r) brand awareness & market share through professionals and consumers

  16. Slide 16: Adams' Performance Against The Strategy

    Slide 16: Adams' Performance Against The Strategy

    Adams' Performance Against The Strategy Mucinex(r) Awareness & Market Share Growth: Achieved 68% consumer awareness in just two years (1) Achieved 97% (2) physician awareness with 64% (1) of users saying they got recommendation for Mucinex(r) from a healthcare professional Number 3 brand in the CCAS

  17. Slide 17: Adams' Performance Against The Strategy: Internal Guaifenesin Pipeline

    Slide 17: Adams' Performance Against The Strategy: Internal Guaifenesin Pipeline

    Adams' Performance Against The Strategy Building Internal Guaifenesin Pipeline: Mucinex(r) line extensions: DM launched in 2004; D launched in 2005; Children's products launched in 2006 Max.-strength products: Humibid(r) SE launched in 2006; D & DM to launch 2006E Development pipeline: 3 significant

  18. Slide 18: Adams' Performance Against The Strategy: In-License/Acquire

    Slide 18: Adams' Performance Against The Strategy: In-License/Acquire

    Adams' Performance Against The Strategy In-License/Acquire New Respiratory Products: In-licensed erdosteine from Edmond Pharma in 2005 In-licensed proprietary Mini-Melt(tm) technology from Losan in 2006 Acquired Delsym(r) from UCB in June 2006 In-licensed Pennkinetic(r) technology from UCB June 2006

  19. Slide 19: Adams' Strategy

    Slide 19: Adams' Strategy

    Adams' Strategy Build internal pipeline by extending guaifenesin platform to other OTC & Rx respiratory segments Access platform technologies to accelerate product development Four - pronged strategy Drive Mucinex(r) brand awareness & market share among professionals and consumers Build Rx business

  20. Slide 20: Financial Outlook: Income Statement Overview

    Slide 20: Financial Outlook: Income Statement Overview

    Financial Outlook: Income Statement Overview Includes $16.1 million tax benefit related to the future benefit of NOLs. Includes $2.5 million after-tax impact of the discretionary performance bonus. $39.2 $52.8 $239.1 $160.2 $61.3 Net Sales 83.5% 79.7% 79.4% 80.6% 80.5% Gross Margin % $4.8 12% $11.0

  21. Slide 21: Strong Growth in Revenues

    Slide 21: Strong Growth in Revenues

    2003 14 2004 61.3 2005 160.2 2006 239.1 2005 39.2 2006 52.8 2002 -15.5 2003 -22.6 2004 35.8 LTM 2003 8.9 2004 9.2 12- Months Ended 3- Months Ended Strong Growth in Revenues (in millions) 6/03 6/05 6/04 6/05 YoY Growth 35% CAGR '03-'05 158 % 6/06 6/06 $239.1 $39.2

  22. Slide 22: Adams Respiratory Therapeutics

    Slide 22: Adams Respiratory Therapeutics

    ADAMS RESPIRATORY THERAPEUTICS™ I\S

Source: SEC EDGAR · 8-K filed Aug 24, 2006

More decks from Adams Respiratory Therapeutics Inc